• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pear Therapeutics touts cost-effectiveness of opioid use disorder treatment

February 23, 2021 By Sean Whooley

Pear Therapeutics today touted analysis of its reSET-O therapeutic for opioid use disorder (OUD) that demonstrated cost-effectiveness.

Boston-based Pear Therapeutics’ reSET-O is the first and only FDA-authorized prescription digital therapeutic for treating OUD, according to a news release.

The analysis, published in Postgraduate Medicine, highlighted that reSET-O and treatment-as-usual (which includes transmucosal buprenorphine, face-to-face counseling and contingency management) decreased total healthcare costs and resulted in improved post-treatment quality-adjusted life-year gains.

Over 12 weeks, a decision-analytic model evaluated the cost-effectiveness of reSET-O relative to treatment-as-usual, with results highlighting population-level gains in quality-adjusted life-years at a lower cost with Pear Therapeutics’ treatment instead of treatment-as-usual by itself.

Additionally, the analysis observed that, on top of clinical value, the results highlighted the limited economic risk of reSET-O in combination with treatment-as-usual.

“OUD is one of the deadliest and costliest health conditions in the United States, generating close to 50,000 deaths and costing an estimated 40 to 70 billion dollars in annual medical costs each year, mostly from the more than 80% of untreated patients. Already high OUD-related deaths jumped after the start of the COVID-19 pandemic, and relapse rates due to the ongoing pandemic are expected to further increase the use of emergency department visits and inpatient stays, which are primary direct cost drivers in OUD,” Pear Therapeutics chief medical officer Dr. Yuri Maricich said in the release. “This analysis showed that reSET-O has the potential to improve population health while reducing costs, further highlighting the importance of providing holistic, low-barrier care to one of our most vulnerable populations.”

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: opioids, peartherapeutics

IN CASE YOU MISSED IT

  • BriaCell Therapeutics closes $25M offering
  • ICU Medical dips despite Street-beating Q4
  • 8 drug delivery innovations you need to know
  • Axonics acquires Contura and its Bulkamid bulking agent for $235M
  • Lilly to add Welldoc app to future insulin pen

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS